Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Window-of-opportunity Proof-of-concept, Non-randomized, Open-label Phase II Trial of Olaparib Given Alone (Cohort A) or in Combination With Durvalumab (Cohort B) Prior to Primary Debulking Surgery in Histologically Proven High-grade Epithelial Ovarian Cancer (EOC)

NCT04644289 is registered in ClinicalTrials.gov with AGO Research GmbH as lead sponsor.

NCT NCT04644289
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04644289 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Window-of-opportunity Proof-of-concept, Non-randomized, Open-label Phase II Trial of Olaparib Given Alone (Cohort A) or in Combination With Durvalumab (Cohort B) Prior to Primary Debulking Surgery in Histologically Proven High-grade Epithelial Ovarian Cancer (EOC)
Lead sponsor
AGO Research GmbH
Phase
Phase 2
Overall status
Recruiting
Start date
May 5, 2022
Completion date
June 30, 2028
Enrollment
60 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

epithelial ovarian cancer